Ryo Okuda1, Hidekazu Matsushima2, Tomohiro Oba3, Rie Kawabe4, Minako Matsubayashi5, Masako Amano6, Tomotaka Nishizawa7, Koujiro Honda8. 1. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: b980013@yahoo.co.jp. 2. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: himatsushima@sunny.ocn.ne.jp. 3. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: obatomohiro@hotmail.co.jp. 4. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: blackberry_wine1218@yahoo.co.jp. 5. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: mizu_mina@hotmail.com. 6. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: skyfield1021@gmail.com. 7. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: tn1230bungo@yahoo.co.jp. 8. Department of Respiratory Medicine, Saitama Red Cross Hospital, 8-3-33 Kami-ochiai, Chuo-ku, Saitama 338-8553, Japan. Electronic address: hondakojiro78@gmail.com.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. The efficacy of N-acetylcysteine in patients with IPF remains controversial. The aim of this research was to investigate the efficacy of inhaled N-acetylcysteine. METHODS: This study was designed as a single-center, single-arm, prospective clinical trial. Each patient who had IPF received 352.4mg of inhaled N-acetylcysteine twice daily. RESULTS: In total, 28 patients were enrolled. The mean values of the respiratory function parameters at the initiation of therapy were as follows: forced vital capacity (FVC), 2.27L and %FVC, 76.2%. The mean change in FVC during 26 weeks prior to the inhaled N-acetylcysteine therapy was -170mL, a significant decrease (p=0.019). The mean change in FVC during 26 weeks after the initiation of inhaled N-acetylcysteine therapy was -70mL (p=0.06). When the patients were classified into two groups according to the degree of decline in FVC (≥100mL vs. <100mL) during the 26-week period prior to the initiation of therapy, inhaled N-acetylcysteine showed a greater efficacy in attenuating FVC decline in the ≥100-mL group than in the <100-mL group. CONCLUSIONS: Inhaled N-acetylcysteine therapy was effective in patients with mild-to-moderate IPF and was more beneficial in patients who had greater declines in FVC before the initiation of therapy. (UMIN title: Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis, UMIN000016706, 2015/03/04.).
BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with few treatment options. The efficacy of N-acetylcysteine in patients with IPF remains controversial. The aim of this research was to investigate the efficacy of inhaled N-acetylcysteine. METHODS: This study was designed as a single-center, single-arm, prospective clinical trial. Each patient who had IPF received 352.4mg of inhaled N-acetylcysteine twice daily. RESULTS: In total, 28 patients were enrolled. The mean values of the respiratory function parameters at the initiation of therapy were as follows: forced vital capacity (FVC), 2.27L and %FVC, 76.2%. The mean change in FVC during 26 weeks prior to the inhaled N-acetylcysteine therapy was -170mL, a significant decrease (p=0.019). The mean change in FVC during 26 weeks after the initiation of inhaled N-acetylcysteine therapy was -70mL (p=0.06). When the patients were classified into two groups according to the degree of decline in FVC (≥100mL vs. <100mL) during the 26-week period prior to the initiation of therapy, inhaled N-acetylcysteine showed a greater efficacy in attenuating FVC decline in the ≥100-mL group than in the <100-mL group. CONCLUSIONS: Inhaled N-acetylcysteine therapy was effective in patients with mild-to-moderate IPF and was more beneficial in patients who had greater declines in FVC before the initiation of therapy. (UMIN title: Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis, UMIN000016706, 2015/03/04.).
Authors: Carmen Veith; Agnes W Boots; Musa Idris; Frederik-Jan van Schooten; Albert van der Vliet Journal: Antioxid Redox Signal Date: 2019-04-05 Impact factor: 8.401
Authors: Omar S Usmani; Martyn F Biddiscombe; Shuying Yang; Sally Meah; Eunice Oballa; Juliet K Simpson; William A Fahy; Richard P Marshall; Pauline T Lukey; Toby M Maher Journal: Respir Res Date: 2018-02-06